What is Nasus Pharma Ltd (NSRX)'s fair-value range?

EvidInvest reads Nasus Pharma Ltd (NSRX)'s market price back into the assumptions behind it — the implied P/E, growth rate and cash yield — using its latest filed financials, then lets you set your own. See the full DCF, Graham number, EPV and multiple-based methods at https://evidinvest.com/valuation/NSRX.

How is Nasus Pharma Ltd (NSRX)'s fair value calculated?

Nasus Pharma Ltd (NSRX)'s fair value is computed with several independent methods — a discounted cash flow (DCF) model, the Graham number, earnings power value (EPV), and valuation multiples such as PE and EV/EBITDA — using data from SEC filings. P/B is optional for non-financial companies and included in the preset range for financial sectors.

Which filing are Nasus Pharma Ltd (NSRX)'s valuation inputs based on?

Inputs come from the FY2025 annual report filed 2026-03-25 (accession 0001493152-26-012559). Source: https://www.sec.gov/Archives/edgar/data/2029039/000149315226012559/

Fair value · Nasus Pharma Ltd (NSRX) · updated 2026-10-29 · from annual report FY2025

Nasus Pharma (NSRX): not enough filed data to read assumptions out of the price yet.

Name: Nasus Pharma Ltd (NSRX) valuation inputs and fair-value methods
Creator: EvidInvest
License: https://evidinvest.com/subscription-terms

These methods need positive earnings and cash flow from the company’s SEC filings. The detailed valuation tools below still work with whatever has been filed.

Check another stock

Inputs come from the FY2025 annual report filed 2026-03-25 (accession 0001493152-26-012559); set your own on the sliders below. Research, not investment advice.

The filing behind these numbers

Nasus Pharma Ltd

Revenue: $1.2B
Diluted EPS: $-0.72
Free cash flow: $-4.9M; operating cash flow − capital expenditure
Diluted shares: 8.0M; weighted average

annual report FY2025 · fiscal year ended 2025-12-31 · filed 2026-03-25 · accession 0001493152-26-012559

Open this filing on sec.gov

Valuation tool: build your own NSRX range

Fair Value Summary

Daily Price — NSRX

$3.32 -60.5% (1Y)

Your range0 of 7 methods

At least two methods need a usable value to draw a range with these inputs.

Range with preset inputs

No preset range for this company yet.

The two ranges are identical because every input sits on a preset.

We don’t tell you what NSRX is worth. Every tab OPENS on what today’s price implies for that method’s key assumption; you decide whether that assumption is reasonable — the growth matrix has NSRX’s filed history and the AI chat will reason it through with you — and the range you build is yours. Our presets are filed history and reference settings, never a recommendation.

Discounted cash flow

$16.45per share

393% above the $3.34 price· outside the ±300% band, left out of the range

Preset inputs — revenue-driven DCF from the latest filing

Implied by today’s price

Starting free cash flow is not positive; the model has nothing to grow, so no growth rate reaches the price.

Not solvable from the price — Starting free cash flow is not positive; the model has nothing to grow, so no growth rate reaches the price. Showing preset inputs.

This method has no key input to read out of the price. The others below do, and you set them yourself: the growth matrix shows what NSRX has actually filed, and the AI chat will reason it through with you.

Your inputs

Free cash flow grows at your stage-1 rate, then your stage-2 rate, then a terminal rate; everything is discounted at your WACC.

Stage-1 growth5.0%

Yearly free-cash-flow growth for the first stage. Starts below zero so a shrinking-cash-flow case — and the rate today’s price implies — can be set.

-20.0%60.0%

Stage-1 years5 yrs

How long stage-1 growth lasts.

1 yrs10 yrs

Stage-2 growth2.5%

Slower growth after stage 1, before the terminal phase.

-20.0%30.0%

Stage-2 years5 yrs

0 yrs10 yrs

Terminal growth2.5%

Growth forever after the two stages. Above ~3% is rarely justified.

0.0%5.0%

Discount rate (WACC)29.81%

The return you require. Default is the WACC EvidInvest computed for this company. Higher discount rate, lower value.

3.00%44.80%

Net debt ($M)Debt minus cash, from the balance sheet. Subtracted from enterprise value.

Starting FCF ($M)Latest free cash flow from the filing (operating cash flow minus capex).

Shares (M)Diluted shares, from the filing.

Year by year (two-stage model, $M)

PV explicit $-18M · PV terminal $-2M · EV $-20M · equity $-19M

Year	Stage	FCF	Present value
1	Stage 1	$-5M	$-4M
2	Stage 1	$-6M	$-3M
3	Stage 1	$-6M	$-3M
4	Stage 1	$-6M	$-2M
5	Stage 1	$-6M	$-2M
6	Stage 2	$-7M	$-1M
7	Stage 2	$-7M	$-1M
8	Stage 2	$-7M	$-1M
9	Stage 2	$-7M	$-1M
10	Stage 2	$-7M	$-1M

Inputs from the filing

Free cash flow: $-4.9M; latest full year
EBIT: $-4.9M; latest annual
Shares: 8.0M
Total debt: $118000
Cash: $1.2M
Net debt: $-1.1M; debt − cash

annual report FY2025 · period ended 2025-12-31 · filed 2026-03-25 · accession 0001493152-26-012559 · sec.gov

Prefer a blank slate with reverse DCF? Open the standalone DCF / reverse DCF for NSRX

Loading history...

Nasus Pharma (NSRX): not enough filed data to read assumptions out of the price yet.

The filing behind these numbers

Valuation tool: build your own NSRX range

Daily Price — NSRX

Your range0 of 7 methods

Range with preset inputs

Your inputs

Year by year (two-stage model, $M)

More on NSRX

Compare with peers

Explore

Valuation tool: build your own NSRX range

Daily Price — NSRX

Your range0 of 7 methods

Range with preset inputs

Your inputs

Year by year (two-stage model, $M)

More on NSRX

Compare with peers

Explore